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TREATMENT OF PROSTATIC CARCINOMA WITH PEPLOMYCIN
    Haruo HlsAzuMi， Kyoichi KuRoDA， Kenji TsuKAHARA＊，
Kimiomi MiyAzAKi＊， Tadao UcHiBAyAsHi＊＊， S．atoshi KosAKA＊＊，
          ．Tadashi TAyA＊“＊ and Kenichi KAMEDA＊＊＊
   Fr・m theエ）吻吻6漉げ研・1・9Pt，5ch・・1〔ゾ醜砒鵬・ぬπα之αωα伽06γ⑳，
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   Peplomycin， a derivative of bleomycin， was used in the treatment of 8 patients with stage D， 2
patients with stage C and one patient with stage B prostatic carcinoma． Newly－diagnosed 4 patients
received peplomycin from the outset and other 7 patients had previously received anti－androgenic
therapy f（）r 4皿onths to 10 years、．Based on the results of a response study using acid－phosphatasc
Ievel， prostatic biopsy， urethrocystography and rectal palpation， there was no objective response in
all of 4 patients given a total dose of 100 mg of peplomycin． Objective responses were elicited in 5
0f 6 patients given a total－dose of 165 to 200 mg of peplomycin． Ilowever， the response was gentle
aqd not so beneficial because of anorexia， which was one of the severe adverse reactions caused by
peplomycin and more or less correlated to the cause of death in 2 of the 6 patients averaging 78 years
of age． To relieve the adverse reaction and enrich the beneficial effect， peplomycin was suggested
to use in combination with other anticancer treatments including irradiation， hyperthermia and／or
anticancer drugs．
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6． Y， Y． 70
7． H．S． 85











































































Table 2． Peplomycin responses evaluated by rectal palpation and urethrocystography































































































Fig． 1 A． A urethrocystogram of case No． 1 before
     treatment． Note a marked elongation
     and deformity of the prostatic urethra．
灘蕪
Fig． 1 B． A urethrocystogram of case No． 1 after
    admin stration of 190 mg of peplomycin．
     Note a considerable improvement of the
     abnormal findings observed before the
     administration．
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Fig． 2 A． A urethrocystogram of case No． 4－before
     treatment． Note a narrowing and elo－
     ngation of the prostatic urethra．
Fig． 2 B． A urethrocystogram of case No．4 after
    administration of 120 mg of peplomycin．
     Note an improvement of the abnormal
     findings of the prostatic urethra．
Table 3． Laboratory data
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Table 4． Laboratory data




4 479 404＊5 428 438
6 466 256＊7 591 359
8 588 278
9 325 252














































Fig． 3 A． Poorly differentiated adenocarcinoma in the prostate of case No． 1 before













          震纏卸町懸
Fig． 3 B． Note slightly degenerate－appearing cells with pyknosis and cytoplasmic vacuolation
  after administration of 165 mg of peplomycin． H ＆ E stain， reduced from ×500．
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Table 5． Adverse reactions and clinical evaluation
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